

Regulatory References
New Zealand, Law Commission. Controlling and regulating drugs
New Zealand, Law Commission. Controlling and regulating drugs: a review of the Misuse of Drugs Act 1975. Wellington, N.Z.: Law Commission 2011.
Board of Health Committee on Drug Dependency and Drug Abuse in New Zealand
First Report. 1970. Available from: https://www.moh.govt.nz/notebook
Woodbridge M, New Zealand, Ministry of Health
Cannabis use 2012/13: New Zealand health survey. 2015. Available from: https://www.health.govt.nz/system/files/documents/publications/cannabis-use-2012-13-nzhs-may15-v2.pdf (Accessed Dec, 2021).
Ministry of Health. Annual Update of Key Results 2019/20
New Zealand Health Survey. Available from: https://www.health.govt.nz/publication/annual-update-key-results-2019-20-new-zealand-health-survey (Accessed Dec, 2021).
New Zealand Legislation. Misuse of Drugs Act 1975.
Available at: https://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html (Accessed Dec, 2021)
Ministry of Health. Medicinal Cannabis Agency. 2021
Available from: https://www.health.govt.nz/our-work/regulation-health-and-disability-system/medicinal-cannabis-agency (Accessed Dec, 2021).
New Zealand Legislation. Misuse of Drugs (Medicinal Cannabis) Regulations 2019
Available from: https://www.legislation.govt.nz/regulation/public/2019/0321/latest/LMS285243.html (Accessed Dec, 2021).8. Schlag AK. An evaluation of regulatory regimes of medical cannabis: what lessons can be learned for the UK? Med Cannabis Cannabinoids 2020;3:76–83. doi:10.1159/000505028
United Nations. Office on Drugs and Crime
Single Convention on Narcotic Drugs, 1961. Available from: https://www.unodc.org/unodc/en/treaties/single-convention.html?ref=menuside (Accessed Dec, 2021).
Ministry of Health. Medicinal cannabis products that meet the minimum quality standard 2021
New Zealand Legislation. Misuse of Drugs Regulations 197 Schedule
1B - Controlled drugs that designated pharmacist prescribers may prescribe. 2021. Available from: https://www.legislation.govt.nz/regulation/public/1977/0037/30.0/DLM5461161.html (Accessed Dec, 2021).
Ministry of Health. Controlled drugs. 2019
Available from: https://www.health.govt.nz/our-work/regulation-health-and-disability-system/medicines-control/controlled-drugs (Accessed Dec, 2021).
Medsafe. Use of Unapproved Medicines and Unapproved Use of Medicines
Available at: https://www.medsafe.govt.nz/profs/RIss/unapp.asp(Accessed Dec, 2021).
Ministry of Health. Medicinal Cannabis Agency - Minimum quality standard 2021


Clinical References
Pisanti S, Malfitano AM, Ciaglia E, et al. Cannabidiol: State of the art and new challenges for therapeutic applications
Pharmacology & Therapeutics 2017;175:133–50. doi:10.1016/j.pharmthera.2017.02.04116. Lu H-C, Mackie K. Review of the endocannabinoid system. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 2020;:S2451902220302068. doi:10.1016/j.bpsc.2020.07.016
Systematic review of systematic reviews for medical cannabinoids: pain, nausea and vomiting, spasticity, and harms
Allan GM, Finley CR, Ton J, et al. Systematic review of systematic reviews for medical cannabinoids: pain, nausea and vomiting, spasticity, and harms. Can Fam Physician 2018;64:e78–94.
Simplified guideline for prescribing medical cannabinoids in primary care
Allan GM, Ramji J, Perry D, et al. Simplified guideline for prescribing medical cannabinoids in primary care. Can Fam Physician 2018;64:111–20.
Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study
Campbell G, Hall WD, Peacock A, et al. Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. The Lancet Public Health 2018;3:e341–50. doi:10.1016/ S2468-2667(18)30110-5
Cannabinoids for nausea and vomiting in cancer patients receiving chemotherapy
Smith LA, Jess CE. Cannabinoids for nausea and vomiting in cancer patients receiving chemotherapy. Cochrane Database of Systematic Reviews 2011;:CD009464. doi:10.1002/14651858.CD009464
Cannabinoid Hyperemesis Syndrome: an update for primary care providers
Lee Stinnett V, Kuhlmann KL. Cannabinoid Hyperemesis Syndrome: an update for primary care providers. The Journal for Nurse Practitioners 2018;14:450–5. doi:10.1016/j.nurpra.2018.01.020
Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis
Zettl UK, Rommer P, Hipp P, et al. Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Ther Adv Neurol Disord 2016;9:9–30. doi:10.1177/1756285615612659
MedSafe. New Zealand Data Sheet
SATIVEX. Available from: https://www.medsafe.govt.nz/profs/datasheet/s/sativexspray.pdf (Accessed Dec, 2021).
Cannabinoids in the treatment of epilepsy: hard evidence at last?
Perucca E. Cannabinoids in the treatment of epilepsy: hard evidence at last? J Epilepsy Res 2017;7:61–76. doi:10.14581/jer.17012
Queensland Government. Clinical Guidance: for the use of medicinal cannabis products in Queensland 2018
Available from: https://www.health.qld.gov. au/__data/assets/pdf_file/0023/634163/med-cannabis-clinical-guide.pdf (Accessed Dec, 2021).
Benefits and harms of medical cannabis: a scoping review of systematic reviews
Pratt M, Stevens A, Thuku M, et al. Benefits and harms of medical cannabis: a scoping review of systematic reviews. Syst Rev 2019;8:320. doi:10.1186/ s13643-019-1243-x
The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research
National Academies of Sciences, Engineering, and Medicine (U.S.), editor. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington, DC: The National Academies Press 2017.
Comparison of acute lethal toxicity of commonly abused psychoactive substances
Gable RS. Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction 2004;99:686–96. doi:10.1111/j.1360-0443.2004.00744.x
Meta-analysis of the association between the level of cannabis use and risk of psychosis
Marconi A, Di Forti M, Lewis CM, et al. Meta-analysis of the association between the level of cannabis use and risk of psychosis. SCHBUL 2016;42:1262–9. doi:10.1093/schbul/sbw003
New Zealand Formulary (NZF)
NZF v114. Available from:www.nzf.org.nz(Accessed Dec, 2021).31. Rein JL. The nephrologist’s guide to cannabis and cannabinoids: Current Opinion in Nephrology and Hypertension 2020;29:248–57. doi:10.1097/ MNH.0000000000000590
Employment New Zealand. Drugs, alcohol and work 2021
Available from: https://www.employment.govt.nz/workplace-policies/tests-and-checks/drugs-alcohol-and-work/ (Accessed Dec, 2021).
Ministry of Transport. New Zealand. Drug driving testing 2021
Available from: https://www.transport.govt.nz/area-of-interest/safety/drug-driving-testing/ (Accessed Dec, 2021).
Ministry of Transport. Drug Driving Advisory Panel
Interim Report 3 Setting Statutory Limits for Blood Drug Concentrations Relating to Impaired Driving. 2020. Available from: https://www.transport.govt.nz/assets/Uploads/Report/InterimReport3.pdf (Accessed Dec, 2021).
New Zealand Legislation. Supplementary Order Paper No 24. Land Transport (Drug Driving) Amendment Bill
Proposed amendments for the consideration of the Committee of the whole House. 2021. Available from: https://legislation.govt.nz/sop/government/2021/0024/latest/whole.html#COWH378895(Accessed Dec, 2021).
Urinary pharmacokinetic profile of cannabinoids following administration of vaporized and oral cannabidiol and vaporized CBD-dominant cannabis
Spindle TR, Cone EJ, Kuntz D, et al. Urinary pharmacokinetic profile of cannabinoids following administration of vaporized and oral cannabidiol and vaporized CBD-dominant cannabis. Journal of Analytical Toxicology 2020;44:109–25. doi:10.1093/jat/bkz080
The pharmacokinetics and the pharmacodynamics of cannabinoids
Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol 2018;84:2477–82. doi:10.1111/bcp.13710
The potential for pharmacokinetic interactions between cannabis products and conventional medications
Qian Y, Gurley BJ, Markowitz JS. The potential for pharmacokinetic interactions between cannabis products and conventional medications. J Clin Psychopharmacol 2019;39:462–71. doi:10.1097/JCP.0000000000001089
Practical considerations in medical cannabis administration and dosing
MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. European Journal of Internal Medicine 2018;49:12–9. doi:10.1016/j.ejim.2018.01.004
Clinical and preclinical evidence for functional interactions of cannabidiol and Δ9-Tetrahydrocannabinol. Neuropsychopharmacol 2018;43:142–54
Boggs DL, Nguyen JD, Morgenson D, et al. Clinical and preclinical evidence for functional interactions of cannabidiol and Δ9-Tetrahydrocannabinol. Neuropsychopharmacol 2018;43:142–54. doi:10.1038/npp.2017.209
Ministry of Health. Medicinal Cannabis Agency - Cannabidiol (CBD) products 2020
Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Vestibulum tortor quam, feugiat vitae, ultricies eget, tempor sit amet, ante. Donec eu libero sit Available from: https://www.health.govt.nz/our-work/regulation-health-and-disability-system/medicinal-cannabis-agency/medicinal-cannabis- agency-information-industry/medicinal-cannabis-agency-working-medicinal- cannabis/medicinal-cannabis-agency-cannabidiol-cbd-products (Accessed Dec, 2021). quam egestas semper. Aenean ultricies mi vitae est. Mauris placerat eleifend leo.
Am I eligible?
Cannabinoids including CBD and THC, extracted from the cannabis plant under strict medical supervision, have been shown to work very well on the symptoms of some chronic medical conditions that conventional prescription medicines have been ineffective at treating.
So, if prescription medicines from your doctor aren’t working for you, Medicinal Cannabis may be a great natural option.
